Tag - TSX

Developments

FDA releases Theratechnologies from EGRIFTA post-approval commitments

The FDA has released Theratechnologies (TSX:TH) from post-approval commitments related to the approval of EGRIFTA. When the FDA approved EGRIFTA in 2010, the agency requested that the company conduct two large safety...

May 1, 2018

Developments

Theratechnologies to seek approval of Trogarzo in Europe

Theratechnologies (TSX:TH) plans to seek regulatory approval from the European Medicines Agency (EMA) for Trogarzo using efficacy and safety data from clinical trials submitted to the FDA. “Based on our discussions, we...

April 24, 2018

Developments

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of...

April 20, 2018

Tag - TSX

FDA releases Theratechnologies from EGRIFTA post-approval commitments

Theratechnologies to seek approval of Trogarzo in Europe

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

General

More